SCHEMBL1974907

SCHEMBL1974907

Cc1cn[nH]c1C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19195028 0.82
SCHEMBL13162008 0.80
SCHEMBL1430587 0.77 TSHR (0.50)
SCHEMBL23798534 0.77 PDPK1 (0.38)
SCHEMBL19913367 0.77 IL1B (0.41)
SCHEMBL10957711 0.74
SCHEMBL5134164 0.74 IL1B (0.45)
SCHEMBL12944436 0.74 GABRP (0.42)
SCHEMBL1973618 0.73
SCHEMBL20929052 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376473-A1 PRMTS INHIBITOR AND USE THEREOF CYTOSINLAB THERAPEUTICS CO LTD (CN) 2025-12-11 US disclosed
EP-3867248-B1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-12-10 EP disclosed
EP-4549442-A1 PRMT5 INHIBITORS AND USE THEREOF Cytosinlab Therapeutics Co., Ltd. (CN) 2025-05-07 EP disclosed
EP-4549440-A1 CLASS OF PRMT5 INHIBITORS AND USE THEREOF Cytosinlab Therapeutics Co., Ltd. (CN) 2025-05-07 EP disclosed
WO-2025057114-A1 PARP1 INHIBITORS AND THE USE IN THE TREATMENT OF CNS DISEASES IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) 2025-03-20 WO disclosed
CN-119562954-A PRMT5 inhibitor and application thereof 上海赛岚生物科技有限公司 2025-03-04 CN disclosed
CN-119487041-A PRMT5 inhibitor and application thereof 上海赛岚生物科技有限公司 2025-02-18 CN disclosed
WO-2024255697-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2024-12-19 WO disclosed
US-20240376126-A1 PRMT5 INHIBITOR AND THE USE THEREOF CYTOSINLAB THERAPEUTICS CO., LTD. (CN) 2024-11-14 US disclosed
US-20240252473-A1 Sulfoximines as inhibitors of NaV1.8 GRUENENTHAL GMBH (DE) 2024-08-01 US disclosed
US-20160009744-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-01-14 US disclosed
WO-2016004136-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME DUFFEY MATTHEW O (US) 2016-01-07 WO disclosed
US-8389513-B2 2-amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)-phenyl]-amides HOFFMANN-LA ROCHE INC. (US) 2013-03-05 US disclosed
EP-2509965-A1 2-AMINO-5, 5-DIFLUORO-5, 6-DIHYDRO-4H-OXAZINES AS BACE 1 AND/OR BACE 2 INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-10-17 EP disclosed
CN-102712609-A 2-amino-5, 5-difluoro-5, 6-dihydro-4H-oxazines as BACE1 and/or BACE2 inhibitors HOFFMANN LA ROCHE 2012-10-03 CN disclosed
US-20110144097-A1 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-16 US disclosed
WO-2011069934-A1 2-AMINO-5, 5-DIFLUORO-5, 6-DIHYDRO-4H-OXAZINES AS BACE 1 AND/OR BACE 2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-16 WO disclosed
WO-2011004323-A1 NEW INHIBITORS OF PROLINE RACEMASE ENZYMES INSTITUT PASTEUR (FR) 2011-01-13 WO disclosed
EP-2272510-A1 Inhibitors of the proline racemase of trypanosoma cruzi Institut Pasteur (FR) 2011-01-12 EP disclosed
WO-2007145349-A2 SUBSTITUTED PYRROLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-12-21 WO disclosed